PA28 modified transgenic mice
AssigneeOrtho-McNeil Pharmaceutical, Inc.
InventorsWai-Ping Leung, Young Yang, Tobias Preckel, Per Peterson
Life of this patent
Estimating the term…
Abstract
A transgenic mouse with alterations in a PA28β gene is prepared by introduction of an altered PA28β gene into a host mouse. The resulting transgenic animals do not produce functional PA28 molecules. Cells and cell lines derived from these animals also contain the altered PA28β gene.
Claims7
A transgenic mouse whose somatic and germ cells comprise a homozygous disruption in the endogenous PA28β gene, wherein said disruption is generated by targeted replacement with a non-functional PA28β gene, and wherein said disruption results in impaired priming of cytotoxic T lymphocytes as compared to priming of cytotoxic T lymphocytes in wild-type PA28β mice.
A method of producing a transgenic mouse whose somatic and germ cells comprise a homozygous disruption in the endogenous PA28β gene, wherein said disruption is generated by targeted replacement with a non-functional PA28β gene, said method comprising:
- (a) introducing a PA28β targeting construct comprising a selectable marker sequence into a mouse embryonic stem cell;
- (b) introducing said embryonic stem cell into a mouse blastocyst;
- (c) transplanting said blastocyst into a recipient mouse;
- and
- (d) allowing said blastocyst to develop to term;
- (e) identifying a transgenic mouse whose genome comprises a disruption in the endogenous PA28β gene in at least one allele;
- and
- (f) breeding the transgenic mouse of step (e) to obtain a transgenic mouse whose genome comprises a homozygous disruption in the endogenous PA28β gene, wherein said disruption results in impaired priming of cytotoxic T lymphocytes as compared to priming of cytotoxic T lymphocytes in wild-type PA28β mice.
Dependencies are inferred from the claim text.